3. Locally advanced or metastatic disease not amenable to surgery with curative intent with measurable disease per RECIST 1.1 (9) as determined by the investigator based on an assessment of all known disease sites by computerized tomography (CT) scan or magnetic resonance imaging (MRI) of chest/abdomen/pelvis within 28 days before the first dose of cabozantinib